TGF‑β signaling‑mediated immune microenvironment remodeling in urological malignancies: A contributor to immunotherapy resistance and a candidate therapeutic target (Review)
Immune checkpoint inhibitors (ICIs) have transformed the treatment of bladder cancer (BC) and renal cell carcinoma (RCC), whereas prostate cancer (PC) remains intrinsically insensitive to ICIs. In patients with BC and RCC, primary and acquired resistance remain formidable clinical challenges. Transforming growth factor‑β (TGF‑β) signaling has emerged as a contributor to immunotherapy refractoriness through its multifaceted remodeling of the tumor immune microenvironment. This pathway orchestrates CD8+ T cell exhaustion, regulatory T cell expansion, macrophage polarization toward immunosuppressive phenotypes, cancer‑associated fibroblast activation with consequent extracellular matrix remodeling, and metabolic reprogramming that sustains a tolerogenic niche. In patients with BC, PC and RCC, TGF‑β pathway activation is correlated with immune exclusion and poor responses to immune checkpoint blockade. Although TGF‑β‑targeted agents, including ligand‑neutralizing antibodies, receptor kinase inhibitors, and TGF‑β‑resistant cellular immunotherapies, have shown encouraging preclinical and early clinical activity, challenges persist regarding on‑target toxicity, the context‑dependent dual functionality of TGF‑β, and the lack of validated predictive biomarkers for patient selection. The present review comprehensively summarizes the mechanisms underlying of TGF‑β‑mediated immune evasion in urological malignancies, critically evaluates current therapeutic strategies and their limitations, and discusses emerging approaches to overcome resistance, thereby informing the rational design of TGF‑β‑targeted immunotherapies.
Authors
- Pengxiao Su
- Yan Li (ORCID: https://orcid.org/0000-0002-4658-2080)
- Xiaoke Sun
Institutions
- Xi'an Honghui Hospital (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- International Journal of Oncology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3892/ijo.2026.5964
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00